DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform

It is estimated that approximately 22,000 Americans will be diagnosed with tumor of the brain or nervous system in 2010. Among primary brain tumors, approximately 60% are gliomas, the most common and most malignant of which is glioblastoma multiforme (GBM).The DecisionDx-GBM test is a multigene expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Allingham-Hawkins, Diane, Lea, Andrew, Levine, Susan
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Evidence on Genomic Tests
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957243/
https://www.ncbi.nlm.nih.gov/pubmed/20972474
http://dx.doi.org/10.1371/currents.RRN1186
Descripción
Sumario:It is estimated that approximately 22,000 Americans will be diagnosed with tumor of the brain or nervous system in 2010. Among primary brain tumors, approximately 60% are gliomas, the most common and most malignant of which is glioblastoma multiforme (GBM).The DecisionDx-GBM test is a multigene expression assay that is designed to predict which patients are likely to experience long-term (> 2 years) progression-free survival.

Ejemplares similares